Article
Predictive role of polymorphic variants of phase II drug metabolising enzyme in modulating toxicity in North Indian lung cancer patients undergoing chemotherapy.
Xenobiotica; the fate of foreign compounds in biological systems - 1 Mar 2022
Walia Harleen, Sharma Parul, Singh Navneet, Sharma Siddharth
Abstract excerpt
Genetic polymorphism of drug-metabolising enzymes such as NQO1, SULT1A1, EPHX1, and NAT2 alters its activity which hampers the detoxification and disposal of chemotherapeutic compounds. Thus, in the present study, we have comprehensively investigated the associations between SNPs of the Phase II detoxifying genes and its relationship towards platinum-induced toxicity of lung cancer patients.NQO1 (609 C > T),...
Topics
- Arylamine N-Acetyltransferase
- Case-Control Studies
- Genotype
- Humans
- Lung Neoplasms
- Pharmaceutical Preparations
- Polymorphism, Single Nucleotide
- Risk Factors